LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Retroperitoneal dedifferentiated liposarcoma.

    Dubois-Silva, Alvaro / Barbagelata-Lopez, Cristina

    Internal and emergency medicine

    2018  Volume 14, Issue 4, Page(s) 619–620

    MeSH term(s) Foot/physiopathology ; Humans ; Liposarcoma/diagnosis ; Liposarcoma/physiopathology ; Liposarcoma/surgery ; Male ; Middle Aged ; Pain/etiology ; Radiography/methods ; Retroperitoneal Neoplasms/diagnosis ; Retroperitoneal Neoplasms/physiopathology ; Retroperitoneal Neoplasms/surgery
    Language English
    Publishing date 2018-12-05
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 2454173-4
    ISSN 1970-9366 ; 1828-0447
    ISSN (online) 1970-9366
    ISSN 1828-0447
    DOI 10.1007/s11739-018-2004-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Outpatient parenteral antimicrobial therapy with continuous infusion of meropenem: A retrospective analysis of three years of clinical experience.

    Dubois-Silva, Álvaro / Otero-Plaza, Lara / Dopico-Santamariña, Leticia / Mozo-Ríos, Ana / Hermida-Porto, Leticia / Feal-Cortizas, Begoña / García-Queiruga, Marta / Pértega-Díaz, Sonia / Lamelo-Alfonsín, Fernando / Vidán-Martínez, Luciano

    Enfermedades infecciosas y microbiologia clinica (English ed.)

    2023  Volume 41, Issue 6, Page(s) 321–328

    Abstract: Introduction: Data regarding outpatient parenteral antimicrobial therapy (OPAT) with continuous infusion of meropenem (CIM) remain scarce and controversial. We aimed to analyze its outcomes.: Methods: We conducted a retrospective analysis of a cohort ...

    Abstract Introduction: Data regarding outpatient parenteral antimicrobial therapy (OPAT) with continuous infusion of meropenem (CIM) remain scarce and controversial. We aimed to analyze its outcomes.
    Methods: We conducted a retrospective analysis of a cohort of patients who received OPAT with CIM during a three-year period at a single center in northwest Spain. Demographics, clinical data and OPAT outcomes were recorded.
    Results: Since January 2017-December 2019, 34 patients received 35 OPAT episodes with CIM. The median age was 75 years, and 18 (51.4%) had a Charlson comorbidity index>2. Twelve (34.3%) had respiratory infection, 11 (31.4%) urinary tract infection, and 12 (34.3%) other infections. Twenty-one (60%) received a dose of 6g/day, and 27 (77.1%) received combined antibiotic therapy. The duration of OPAT with CIM was 10 median days. Pseudomonas aeruginosa was the most frequently (34.3%) isolated microorganism and 10 (28.6%) infections were polymicrobial. During OPAT and hospital at home unit admission, 4 (11.4%) patients had any adverse reaction that required CIM withdrawal, 2 (5.7%) were readmitted, and 3 (8.8%) died (2 infection-related deaths). After 30 days from discharge 6 (18.8%) of 32 not-censored patients had unplanned readmissions (2 infection-related), 6 (18.8%) developed recurrence (3 relapses, 3 reinfections) and 1 (3.1%) died (none-infection-related death). Twenty-three (71.9%) of these 32 patients did not experience unplanned readmission, recurrence or death.
    Conclusion: CIM can be an option to be administrated in OPAT programs in selected patients. Further studies are warranted to increase evidence regarding its use, and to externally validate our findings.
    MeSH term(s) Humans ; Aged ; Meropenem ; Outpatients ; Retrospective Studies ; Prospective Studies ; Anti-Infective Agents/therapeutic use
    Chemical Substances Meropenem (FV9J3JU8B1) ; Anti-Infective Agents
    Language English
    Publishing date 2023-01-05
    Publishing country Spain
    Document type Journal Article
    ISSN 2529-993X
    ISSN (online) 2529-993X
    DOI 10.1016/j.eimce.2021.11.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019.

    Dubois-Silva, Álvaro / Barbagelata-López, Cristina / Mena, Álvaro / Piñeiro-Parga, Patricia / Llinares-García, Diego / Freire-Castro, Santiago

    Internal and emergency medicine

    2020  Volume 15, Issue 5, Page(s) 865–870

    MeSH term(s) Aged ; Anticoagulants/therapeutic use ; COVID-19 ; Comorbidity ; Coronavirus Infections/diagnosis ; Coronavirus Infections/epidemiology ; Coronavirus Infections/therapy ; Cross-Sectional Studies ; Female ; Follow-Up Studies ; Hospitals, University ; Humans ; Inpatients/statistics & numerical data ; Intensive Care Units ; Male ; Mass Screening/methods ; Middle Aged ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/therapy ; Prevalence ; Pulmonary Embolism/diagnostic imaging ; Pulmonary Embolism/drug therapy ; Pulmonary Embolism/epidemiology ; Risk Assessment ; Severity of Illness Index ; Spain/epidemiology ; Survival Analysis ; Tomography, X-Ray Computed/methods ; Venous Thrombosis/diagnostic imaging ; Venous Thrombosis/drug therapy ; Venous Thrombosis/epidemiology
    Chemical Substances Anticoagulants
    Keywords covid19
    Language English
    Publishing date 2020-06-26
    Publishing country Italy
    Document type Letter ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 2454173-4
    ISSN 1970-9366 ; 1828-0447
    ISSN (online) 1970-9366
    ISSN 1828-0447
    DOI 10.1007/s11739-020-02416-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Deep vein thrombosis symptoms and 30-day mortality in acute pulmonary embolism.

    Dubois-Silva, Álvaro / Barbagelata-López, Cristina / Piñeiro-Parga, Patricia / López-Jiménez, Luciano / Riera-Mestre, Antoni / Schellong, Sebastian / Catella, Judith / Bosevski, Marijan / Roca Toledo, Mireia / Monreal, Manuel

    European journal of internal medicine

    2022  Volume 108, Page(s) 43–51

    Abstract: Background: In patients with acute symptomatic pulmonary embolism (PE), the presence of concomitant lower-limb deep vein thrombosis (DVT) has been associated with a higher mortality rate. The prognostic significance of DVT symptoms among these patients ... ...

    Abstract Background: In patients with acute symptomatic pulmonary embolism (PE), the presence of concomitant lower-limb deep vein thrombosis (DVT) has been associated with a higher mortality rate. The prognostic significance of DVT symptoms among these patients remains uncertain.
    Methods: We used the RIETE (Registro Informatizado de Enfermedad TromboEmbólica) registry to compare the 30-day mortality rate in patients with PE and concomitant lower-limb DVT, according to the presence or absence of DVT symptoms. Primary outcomes were all-cause death and PE-related death within the first 30 days.
    Results: Since March 2001 to June 2021, there were 17,742 patients with acute symptomatic PE and objectively proven concomitant lower-limb DVT. Of these, 11,984 (68%) had DVT symptoms. Most patients with or without DVT symptoms (82% vs. 81%) received low-molecular-weight heparin initially. Then, most (61% vs. 58%) switched to vitamin K antagonists. During the first 30 days of therapy, 497 patients with DVT symptoms (4.1%) and 164 (2.8%) with no DVT symptoms died (rate ratio [RR]: 1.48; 95%CI: 1.23-1.77). The rates of PE-related death were: 1.0% vs. 0.7%, respectively (RR: 1.50; 95%CI: 1.04-2.16). On multivariable analysis, patients with DVT symptoms were at increased risk for all-cause death (adjusted hazard ratio [aHR]: 1.49; 95%CI: 1.24-1.78), and PE-related death (aHR: 1.52; 95%CI: 1.05-2.20).
    Conclusion: Among patients with acute symptomatic PE and concomitant lower-limb DVT, those with DVT symptoms had an increased all-cause and PE-related mortality within 30 days. Assessment of DVT symptoms would assist with risk stratification of these patients.
    MeSH term(s) Humans ; Pulmonary Embolism ; Venous Thrombosis/complications ; Prognosis ; Anticoagulants/therapeutic use ; Fibrinolytic Agents ; Acute Disease ; Risk Factors
    Chemical Substances Anticoagulants ; Fibrinolytic Agents
    Language English
    Publishing date 2022-11-16
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2022.11.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs.

    Dubois-Silva, Álvaro / Barbagelata-López, Cristina / Piñeiro-Parga, Patricia / Francisco, Iria / Falgá, Conxita / Tirado, Raimundo / Suriñach, José María / Vela, Jerónimo Ramón / Mella, Carmen / Quere, Isabelle / Siniscalchi, Carmine / Monreal, Manuel

    Thrombosis and haemostasis

    2021  Volume 121, Issue 12, Page(s) 1650–1659

    Abstract: Background: The prognostic significance of concomitant superficial vein thrombosis (SVT) in patients with lower-limb deep vein thrombosis (DVT) has not been consistently evaluated.: Methods: We used the RIETE (Registro Informatizado de Enfermedad ... ...

    Abstract Background: The prognostic significance of concomitant superficial vein thrombosis (SVT) in patients with lower-limb deep vein thrombosis (DVT) has not been consistently evaluated.
    Methods: We used the RIETE (Registro Informatizado de Enfermedad TromboEmbólica) registry to compare the rates of subsequent pulmonary embolism (PE), recurrent DVT, major bleeding or death in patients with lower-limb DVT, according to the presence or absence of concomitant SVT.
    Results: From March 2015 to May 2020, there were 8,743 patients with lower-limb DVT. Of these, 745 (8.5%) had concomitant SVT. Most patients (97.4% in both subgroups) received anticoagulant therapy (median duration: 138 vs. 147 days). During follow-up (median: 193 vs. 210 days), 156 (1.8%) patients developed subsequent PE, 336 (3.8%) had recurrent DVT, 201 (2.3%) had major bleeding and 844 (9.7%) died. Patients with concomitant SVT had a higher rate of subsequent PE (rate ratio [RR]: 2.11; 95% confidence interval [95%CI]: 1.33-3.24) than those with isolated DVT, with no significant differences in the rates of recurrent DVT (RR: 0.80; 95%CI: 0.50-1.21), major bleeding (RR: 0.77; 95%CI: 0.41-1.33) or death (RR: 0.81; 95%CI: 0.61-1.06). On multivariable analysis, patients with DVT and SVT concomitantly were at increased risk of subsequent PE during anticoagulation (adjusted hazard ratio [HR]: 2.23; 95%CI: 1.22-4.05) and also during the entire follow-up period (adjusted HR: 2.33; 95%CI: 1.49-3.66).
    Conclusion: Patients with lower-limb DVT and SVT concomitantly are at increased risk of developing PE. Further studies are needed to externally validate our findings and to determine if these patients could benefit from a different management strategy.
    MeSH term(s) Aged ; Aged, 80 and over ; Female ; Hemorrhage/epidemiology ; Humans ; Male ; Middle Aged ; Prognosis ; Pulmonary Embolism/diagnosis ; Pulmonary Embolism/epidemiology ; Pulmonary Embolism/mortality ; Recurrence ; Registries ; Risk Assessment ; Risk Factors ; Time Factors ; Venous Thrombosis/diagnosis ; Venous Thrombosis/epidemiology ; Venous Thrombosis/mortality
    Language English
    Publishing date 2021-04-30
    Publishing country Germany
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/a-1414-5055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019

    Dubois-Silva, Álvaro / Barbagelata-López, Cristina / Mena, Álvaro / Piñeiro-Parga, Patricia / Llinares-García, Diego / Freire-Castro, Santiago

    Intern Emerg Med

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #615889
    Database COVID19

    Kategorien

  7. Article: Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs

    Dubois-Silva, Álvaro / Barbagelata-López, Cristina / Piñeiro-Parga, Patricia / Francisco, Iria / Falgá, Conxita / Tirado, Raimundo / Suriñach, José María / Vela, Jerónimo Ramón / Mella, Carmen / Quere, Isabelle / Siniscalchi, Carmine / Monreal, Manuel

    Thrombosis and Haemostasis

    2021  Volume 121, Issue 12, Page(s) 1650–1659

    Abstract: Background: The prognostic significance of concomitant superficial vein thrombosis (SVT) in patients with lower-limb deep vein thrombosis (DVT) has not been consistently evaluated.: Methods: We used the RIETE (Registro Informatizado de Enfermedad ... ...

    Abstract Background: The prognostic significance of concomitant superficial vein thrombosis (SVT) in patients with lower-limb deep vein thrombosis (DVT) has not been consistently evaluated.
    Methods: We used the RIETE (Registro Informatizado de Enfermedad TromboEmbólica) registry to compare the rates of subsequent pulmonary embolism (PE), recurrent DVT, major bleeding or death in patients with lower-limb DVT, according to the presence or absence of concomitant SVT.
    Results: From March 2015 to May 2020, there were 8,743 patients with lower-limb DVT. Of these, 745 (8.5%) had concomitant SVT. Most patients (97.4% in both subgroups) received anticoagulant therapy (median duration: 138 vs. 147 days). During follow-up (median: 193 vs. 210 days), 156 (1.8%) patients developed subsequent PE, 336 (3.8%) had recurrent DVT, 201 (2.3%) had major bleeding and 844 (9.7%) died. Patients with concomitant SVT had a higher rate of subsequent PE (rate ratio [RR]: 2.11; 95% confidence interval [95%CI]: 1.33–3.24) than those with isolated DVT, with no significant differences in the rates of recurrent DVT (RR: 0.80; 95%CI: 0.50–1.21), major bleeding (RR: 0.77; 95%CI: 0.41–1.33) or death (RR: 0.81; 95%CI: 0.61–1.06). On multivariable analysis, patients with DVT and SVT concomitantly were at increased risk of subsequent PE during anticoagulation (adjusted hazard ratio [HR]: 2.23; 95%CI: 1.22–4.05) and also during the entire follow-up period (adjusted HR: 2.33; 95%CI: 1.49–3.66).
    Conclusion: Patients with lower-limb DVT and SVT concomitantly are at increased risk of developing PE. Further studies are needed to externally validate our findings and to determine if these patients could benefit from a different management strategy.
    Keywords anticoagulants ; deep vein thrombosis ; pulmonary embolism ; recurrences ; superficial vein thrombosis
    Language English
    Publishing date 2021-03-07
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 518294-3
    ISSN 2567-689X ; 0340-6245
    ISSN (online) 2567-689X
    ISSN 0340-6245
    DOI 10.1055/a-1414-5055
    Database Thieme publisher's database

    More links

    Kategorien

To top